Stockscreener 앱 받기
0.8209
11.66%
-0.1084
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) | LXRX Stock News - GuruFocus
Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - TradingView
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31% - simplywall.st
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple - MarketScreener
Lexicon Pharmaceuticals surges 67% following InvestingPro’s Fair Value signal By Investing.com - Investing.com
Lexicon Pharmaceuticals at Jefferies Conference: Strategic Partnerships and Pipeline Progress - Investing.com Canada
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Northern Trust Corp - Defense World
Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential - MSN
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Lexicon (LXRX) Advances Study on Sotagliflozin for Heart Conditions | LXRX Stock News - GuruFocus
LXRXLexicon Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts - simplywall.st
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance
Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk - MSN
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lexicon Pharmaceuticals (LXRX) Reports Higher Q1 Revenue and Key Strategic Developments | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals (LXRX) Pre-Earnings Options Activity Rev - GuruFocus
LEXICON PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Lexicon Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Bought by Barclays PLC - Defense World
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlig - GuruFocus
Lexicon: Q1 Earnings Snapshot - New Haven Register
Lexicon Pharmaceuticals (LXRX) Secures Major Licensing Deal with Novo Nordisk - GuruFocus
Lexicon Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LXRX) - Seeking Alpha
Earnings call transcript: Lexicon Q1 2025 beats EPS expectations, stock declines - Investing.com
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings: EPS Beats E - GuruFocus
Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Lexicon Pharmaceuticals Q1 Operating Income USD -25.679 Million - marketscreener.com
Lexicon Secures Massive $1B Novo Nordisk Partnership While Advancing Breakthrough Pain Drug Trial - Stock Titan
A Preview Of Lexicon Pharmaceuticals's Earnings - Nasdaq
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - The Manila Times
Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference | LXRX Stock News - GuruFocus
Lexicon Pharmaceuticals Announces Exclusive Fireside Chat at HC Wainwright BioConnect Conference - Stock Titan
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times
Lexicon Pharmaceuticals Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Carcinoid Syndrome Diarrhea Treatment Market To Reach US$ - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lexicon Pharmaceuticals, Inc. (LXRX)Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action & Lead Plaintiff Deadline: April 1, 2019 - ACCESS Newswire
Top 2 Health Care Stocks That May Crash This Month - Benzinga
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider
Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada
1.11%
1.70%
자본화:
|
볼륨(24시간):